GlassScriptPhysician profile
Richard M Stober
NPI 1255332268
$11,713.90
in general payments reported to CMS, 2019-2025
48 companies · $2,587 in 2025
The $2,587 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,882 · 2020: $1,059 · 2021: $572 · 2022: $1,124 · 2023: $2,098 · 2024: $2,392 · 2025: $2,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,977 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,976.69 |
| Education | $100.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,334.32 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,459.33 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $849.63 | 2022-2024 | |
| Esperion Therapeutics, INC. | $829.47 | 2020-2025 | Nexletol |
| Abbvie INC. | $646.02 | 2019-2025 | Vraylar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $578.36 | 2019-2025 | Jardiance, Ofev, Jascayd |
| Janssen Pharmaceuticals, INC | $545.94 | 2019-2022 | |
| Lilly USA, LLC | $464.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $406.41 | 2019-2025 | Repatha, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $391.28 | 2019-2025 | |
| Pfizer INC. | $373.09 | 2019-2025 | |
| Abbott Laboratories | $340.51 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sumitomo Pharma America, INC. | $259.88 | 2024-2025 | Gemtesa, Myfembree |
| Amneal Pharmaceuticals LLC | $212.80 | 2019-2025 | Unithroid |
| Glaxosmithkline, LLC. | $203.53 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $172.75 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $149.39 | 2019 | |
| Dexcom, INC. | $132.74 | 2023-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $132.51 | 2023-2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $126.34 | 2019-2023 | Veozah, Myrbetriq |
| Ablative Solutions, INC. | $109.09 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.33 | 2019-2025 | Xifaxan |
| Ionis Pharmaceuticals, INC. | $72.42 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $69.14 | 2023-2024 | Rexulti |
| Dynavax Technologies Corporation | $62.88 | 2023-2025 | Heplisav-B |
| Lundbeck LLC | $56.07 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $55.84 | 2024 | Voquezna |
| Xeris Pharmaceuticals, INC. | $48.63 | 2024-2025 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $48.27 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.98 | 2019-2025 | Vpriv |
| Axsome Therapeutics, INC. | $47.55 | 2024-2025 | Auvelity |
| Shield Therapeutics INC | $44.33 | 2022-2023 | Accrufer |
| Madrigal Pharmaceuticals | $39.56 | 2024 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $36.25 | 2019-2023 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $35.33 | 2024-2025 | Uptravi, Opsumit |
| Ascendis Pharma Endocrinology INC | $29.30 | 2023 | |
| Ucb, INC. | $27.70 | 2024 | Nayzilam |
| Hikma Pharmaceuticals USA | $25.68 | 2019-2023 | Mitigare |
| Regeneron Healthcare Solutions, INC. | $22.21 | 2025 | Evkeeza |
| Biohaven Pharmaceutical Holding Company LTD. | $21.16 | 2022 | |
| Optinose US, INC. | $20.19 | 2024 | |
| Azurity Pharmaceuticals, INC. | $17.82 | 2023 | Edarbi |
| Pulmonx Corporation | $16.06 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Kowa Pharmaceuticals America, INC. | $15.53 | 2025 | Zoryve |
| Promius Pharma LLC | $15.46 | 2019 | |
| Ibsa Pharma INC. | $14.10 | 2023 | Tirosint, Licart |
| Shire North American Group INC | $13.07 | 2019 | |
| Travere Therapeutics, INC. | $1.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Stober listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.